Literature DB >> 27755777

Transbronchial needle aspiration with or without endobronchial ultrasound.

Ko Pen Wang1, Robert Browning1.   

Abstract

Transbronchial needle aspiration (TBNA) has been used for over three decades in the diagnosis and staging of mediastinal adenopathy and masses. Although first described in Argentina in 1949 by Dr. Eduardo Schieppati, this rigid bronchoscope technique received very little attention until 1978 at Johns Hopkins Hospital where Wang and colleagues described in detail the diagnosis of a paratracheal mass by TBNA biopsy through a rigid bronchoscope using a 25-gauge esophageal variceal needle. In 1983, a novel flexible needle that could be used with the flexible bronchoscope to perform TBNA was developed and introduced for diagnosis and staging of bronchogenic carcinoma. Immediately to follow was the expansion of its use in the diagnosis of peripheral pulmonary nodules and benign mediastinum and hilar disorders by obtaining histological core specimens. Recent development of the endobronchial ultrasound-guided TBNA is most exciting and promising. Whether this will enhance the result of TBNA and spread the TBNA technique as a standard lung cancer staging procedure is yet to be seen. TBNA is simpler and easier. Endobronchial ultrasound-guided TBNA currently is more complicated and more difficult. Its future relies on a hybrid instrument and methodology to be widely applied to the diagnosis and staging of bronchogenic carcinoma. © Tianjin Lung Cancer Institute and Blackwell Publishing Asia Pty. Ltd.

Entities:  

Keywords:  Bronchoscopy; EBUS; transbronchial needle aspiration

Year:  2010        PMID: 27755777     DOI: 10.1111/j.1759-7714.2010.00015.x

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  1 in total

1.  Conventional transbronchial needle aspiration is promising for identifying EGFR mutations in lung adenocarcinoma.

Authors:  Li-Han Hsu; Jen-Sheng Ko; Chia-Chuan Liu; An-Chen Feng; Nei-Min Chu
Journal:  Thorac Cancer       Date:  2019-02-27       Impact factor: 3.500

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.